Aralez Pharmaceuticals Inc.
ARLZ
ARLZ was delisted on the 20th of August, 2018.
48 hedge funds and large institutions have $1.8M invested in Aralez Pharmaceuticals Inc. in 2018 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 13 increasing their positions, 12 reducing their positions, and 12 closing their positions.
8% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 12
1% less call options, than puts
Call options by funds: $66K | Put options by funds: $67K
14% less funds holding
Funds holding: 56 → 48 (-8)
67% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 12
89% less capital invested
Capital invested by funds: $16M → $1.8M (-$14.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Salzhauer Michael
|
+$228K |
| 2 |
SCP
Silverleafe Capital Partners
Germantown,
Tennessee
|
+$82K |
| 3 |
Renaissance Technologies
New York
|
+$76K |
| 4 |
Millennium Management
New York
|
+$45K |
| 5 |
GT
Glenmede Trust
Philadelphia,
Pennsylvania
|
+$42.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
PAR Capital Management
Boston,
Massachusetts
|
-$3.24M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
-$468K |
| 3 |
JAM
JW Asset Management
Miami Beach,
Florida
|
-$434K |
| 4 |
DZ Bank
Frankfurt Am Main,
Germany
|
-$425K |
| 5 |
BAS
Brown Advisory Securities
Baltimore,
Maryland
|
-$408K |
ARLZ Hedge Fund Activity: Q2 2018 in Review
48 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in Aralez Pharmaceuticals Inc. (ARLZ) for Q2 2018, worth a combined $1.8M — down 89% from $16M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of ARLZ and 4 opened new positions — a net loss of 8 holders — while 12 trimmed existing stakes and 13 added.
The largest buyer was Salzhauer Michael, adding an estimated $228K. The largest seller was PAR Capital Management, cutting an estimated $3.24M.
- 48 institutional investors held Aralez Pharmaceuticals Inc. (ARLZ) as of Q2 2018, down from 56 in Q1 2018.
- Funds reported $1.8M of Aralez Pharmaceuticals Inc. stock for Q2 2018, down 89% quarter-over-quarter.
- 4 funds opened new Aralez Pharmaceuticals Inc. positions in Q2 2018 and 12 closed out, a net change of -8 holders.
- The largest Aralez Pharmaceuticals Inc. buyer in Q2 2018 was Salzhauer Michael, an estimated $228K added.
- The largest Aralez Pharmaceuticals Inc. seller in Q2 2018 was PAR Capital Management, an estimated $3.24M sold.
Based on aggregated 13F filings for Q2 2018.